|Great Point Company||Description||Invested||Status|
APT Pharmaceuticals, Inc.
|APT is a leading specialty pharmaceuticals business focusing on rare lung diseases. APT is developing Pulminiq, a proprietary formulation of inhaled cyclosporine, for prevention of chronic rejection and death in lung transplant patients. Pulminiq is entering a pivotal Phase 3 trial in approximately 150 patients at leading lung transplant centers worldwide. APT is also developing other pulmonary products.||2007||Acquired by MEI Pharma|
View Web Site
|Biodel's first product is a rapid acting injectable insulin called Viaject™. Viaject™ is designed to speed the delivery of insulin into the blood and will compete in the multi-billion dollar rapid acting insulin market. The Company has been financed with growth equity from Great Point Partners.||2006||IPO 2007|